Geron (GERN) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
- Closed at $1.23, +3.36% vs the prior close of $1.19.
- Volume 5.68M shares, 0.6x its 50-day average (light).
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
GERN jumps 3.4% to $1.23. Closed at $1.23, +3.36% vs the prior close of $1.19. Day range $1.20–$1.24, opened at $1.20.
GERN daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — GERN jumps 3.4% to $1.23
- Closed at $1.23, +3.36% vs the prior close of $1.19. Day range $1.20–$1.24, opened at $1.20.
- Volume was 5.68M shares, 0.6x its 50-day average of 10.09M — lighter than usual.
- Price is -11.3% vs its 50-day average ($1.39) and -14.5% vs its 200-day average ($1.44).
- 52-week range $1.04–$2.01; today's close sits at 20% of that range, 38.8% below the 52-week high.
Oct 14, 2026 — GERN dips 0.8% to $1.19, a 3-month low, 3 down days in a row
- Closed at $1.19, -0.83% vs the prior close of $1.20. Day range $1.17–$1.21, opened at $1.20.
- Volume was 5.42M shares, 0.5x its 50-day average of 10.25M — lighter than usual.
- Price is -14.7% vs its 50-day average ($1.40) and -17.3% vs its 200-day average ($1.44).
- 52-week range $1.04–$2.01; today's close sits at 15% of that range, 40.8% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — GERN dips 1.6% to $1.20
- Closed at $1.20, -1.64% vs the prior close of $1.22. Day range $1.18–$1.23, opened at $1.22.
- Volume was 7.58M shares, 0.7x its 50-day average of 10.49M.
- Price is -14.2% vs its 50-day average ($1.40) and -16.7% vs its 200-day average ($1.44).
- 52-week range $1.04–$2.01; today's close sits at 16% of that range, 40.3% below the 52-week high.
Oct 12, 2026 — GERN dips 0.8% to $1.22
- Closed at $1.22, -0.81% vs the prior close of $1.23. Day range $1.21–$1.24, opened at $1.22.
- Volume was 3.98M shares, 0.4x its 50-day average of 10.80M — lighter than usual.
- Price is -12.9% vs its 50-day average ($1.40) and -15.4% vs its 200-day average ($1.44).
- 52-week range $1.04–$2.01; today's close sits at 19% of that range, 39.3% below the 52-week high.
Oct 9, 2026 — GERN rises 0.8% to $1.23
- Closed at $1.23, +0.82% vs the prior close of $1.22. Day range $1.21–$1.26, opened at $1.22.
- Volume was 5.64M shares, 0.5x its 50-day average of 11.08M — lighter than usual.
- Price is -12.2% vs its 50-day average ($1.40) and -14.7% vs its 200-day average ($1.44).
- 52-week range $1.04–$2.01; today's close sits at 20% of that range, 38.8% below the 52-week high.
Oct 8, 2026 — GERN rises 1.7% to $1.22
- Closed at $1.22, +1.67% vs the prior close of $1.20. Day range $1.17–$1.22, opened at $1.21.
- Volume was 10.16M shares, 0.9x its 50-day average of 10.99M.
- Price is -13.1% vs its 50-day average ($1.40) and -15.4% vs its 200-day average ($1.44).
- 52-week range $1.04–$2.01; today's close sits at 19% of that range, 39.3% below the 52-week high.
Oct 7, 2026 — GERN dips 0.8% to $1.20
- Closed at $1.20, -0.83% vs the prior close of $1.21. Day range $1.19–$1.22, opened at $1.21.
- Volume was 5.14M shares, 0.5x its 50-day average of 10.99M — lighter than usual.
- Price is -14.7% vs its 50-day average ($1.41) and -16.8% vs its 200-day average ($1.44).
- 52-week range $1.04–$2.01; today's close sits at 16% of that range, 40.3% below the 52-week high.
Oct 6, 2026 — GERN ends flat (+0.0%) to $1.21
- Closed at $1.21, +0.00% vs the prior close of $1.21. Day range $1.19–$1.24, opened at $1.20.
- Volume was 5.72M shares, 0.5x its 50-day average of 11.05M — lighter than usual.
- Price is -14.3% vs its 50-day average ($1.41) and -16.2% vs its 200-day average ($1.44).
- 52-week range $1.04–$2.01; today's close sits at 18% of that range, 39.8% below the 52-week high.
Oct 5, 2026 — GERN rises 0.8% to $1.21
- Closed at $1.21, +0.83% vs the prior close of $1.20. Day range $1.18–$1.23, opened at $1.20.
- Volume was 6.37M shares, 0.6x its 50-day average of 10.99M — lighter than usual.
- Price is -14.6% vs its 50-day average ($1.42) and -16.2% vs its 200-day average ($1.44).
- 52-week range $1.04–$2.01; today's close sits at 18% of that range, 39.8% below the 52-week high.
Oct 2, 2026 — GERN dips 0.8% to $1.20, a 3-month low, 6 down days in a row
- Closed at $1.20, -0.83% vs the prior close of $1.21. Day range $1.19–$1.22, opened at $1.21.
- Volume was 14.72M shares, 1.4x its 50-day average of 10.78M.
- Price is -15.6% vs its 50-day average ($1.42) and -17.0% vs its 200-day average ($1.45).
- 52-week range $1.04–$2.01; today's close sits at 16% of that range, 40.3% below the 52-week high.
- That makes 6 straight losses.
GERN latest news & SEC filings
Every SEC filing by or about GERN in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 1, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Spiegel Robert J. received an award of 6,351 shares at $1.23 (≈$7.81K) on Sep 30, 2026; now holds 212,161
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 7, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 6, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Aug 5, 2026 · Form S-8 — Employee share plan registration
Registration of shares for employee stock plans (S-8)
Aug 5, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $57.48M (prior year $49.04M) (+17.2% vs Jun 30, 2025)
- Net income: -$16.68M (prior year -$16.38M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$0.02 (prior year -$0.02) ( vs Jun 30, 2025)
Jul 1, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Things to know before you trade GERN
- Last results release: Aug 6, 2026 (8-K Item 2.02). Previous ones: Feb 25, 2026, Nov 5, 2025, Aug 6, 2025. Based on that rhythm, the next report is likely around Nov 5, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 1.24% (largest 5.3%).
- Liquidity: about 8.63M shares (≈$10.61M) trade per day on average.
- 52-week position: $1.23 vs a range of $1.04–$2.01 (20% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 1 sales; latest: Michelle Robertson sold 9,855 shares on Feb 18, 2026.
- Latest filings: 8-K Aug 6, 2026; 10-Q Aug 5, 2026; 8-K May 27, 2026.
- Share count: 642.47M shares outstanding (Jul 31, 2026), +0.7% vs a year earlier.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
GERN market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 1.20 | 1.24 | 1.20 | 1.23 | 5.68M |
| Oct 14, 2026 | 1.20 | 1.21 | 1.17 | 1.19 | 5.42M |
| Oct 13, 2026 | 1.22 | 1.23 | 1.18 | 1.20 | 7.58M |
| Oct 12, 2026 | 1.22 | 1.24 | 1.21 | 1.22 | 3.98M |
| Oct 9, 2026 | 1.22 | 1.26 | 1.21 | 1.23 | 5.64M |
| Oct 8, 2026 | 1.21 | 1.22 | 1.17 | 1.22 | 10.16M |
| Oct 7, 2026 | 1.21 | 1.22 | 1.19 | 1.20 | 5.14M |
| Oct 6, 2026 | 1.20 | 1.24 | 1.19 | 1.21 | 5.72M |
| Oct 5, 2026 | 1.20 | 1.23 | 1.18 | 1.21 | 6.37M |
| Oct 2, 2026 | 1.21 | 1.22 | 1.19 | 1.20 | 14.72M |
| Oct 1, 2026 | 1.24 | 1.25 | 1.19 | 1.21 | 13.25M |
| Sep 30, 2026 | 1.26 | 1.27 | 1.23 | 1.23 | 9.44M |
| Sep 29, 2026 | 1.26 | 1.26 | 1.21 | 1.24 | 12.49M |
| Sep 28, 2026 | 1.27 | 1.27 | 1.22 | 1.25 | 9.97M |
| Sep 25, 2026 | 1.26 | 1.27 | 1.24 | 1.26 | 10.30M |
| Sep 24, 2026 | 1.23 | 1.27 | 1.20 | 1.26 | 6.41M |
| Sep 23, 2026 | 1.33 | 1.33 | 1.22 | 1.24 | 10.93M |
| Sep 22, 2026 | 1.32 | 1.33 | 1.29 | 1.31 | 6.22M |
| Sep 21, 2026 | 1.30 | 1.31 | 1.28 | 1.30 | 5.89M |
| Sep 18, 2026 | 1.32 | 1.33 | 1.29 | 1.30 | 17.24M |
About Geron
Geron (GERN) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in FOSTER CITY, CA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 886744.
GERN board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Patricia S Andrews | Director | Mar 26, 2026 |
| Dawn Carter Bir | Director | May 26, 2026 |
| Constantine Chinoporos | Director | Mar 26, 2026 |
| John F Mcdonald | Director | May 26, 2026 |
| Susan Molineaux | Director | May 26, 2026 |
| Elizabeth G. O'Farrell | Director | May 26, 2026 |
| Robert J. Spiegel | Director | Jul 1, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Joseph Eid | EVP, R&D; Chief Medical Office | Feb 19, 2026 |
| Ahmed Elnawawi | EVP, Chief Commercial Officer | Oct 20, 2025 |
| Michelle Robertson | EVP, CHIEF FINANCIAL OFFICER | Feb 19, 2026 |
| Timothy Williams | EVP and Chief Legal Officer | Apr 14, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Feb 18, 2026 | Michelle Robertson | Sale | 9,855 | $1.94 |
GERN financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-83.50M | -0.13 | $-111.04M |
| Dec 31, 2024 | — | $-174.57M | -0.27 | $-218.62M |
| Dec 31, 2023 | $237.00K | $-184.13M | -0.32 | $-167.74M |
| Dec 31, 2022 | $596.00K | $-141.90M | -0.37 | $-127.38M |
| Dec 31, 2021 | $1.39M | $-116.11M | -0.35 | $-95.56M |
Latest balance sheet: total assets $519.01M, total liabilities $300.39M, cash $62.64M (as of Jun 30, 2026).
GERN earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 6, 2026 | 8-K Item 2.02 (results) | $1.57 |
| Feb 25, 2026 | 8-K Item 2.02 (results) | $1.72 |
| Nov 5, 2025 | 8-K Item 2.02 (results) | $1.09 |
| Aug 6, 2025 | 8-K Item 2.02 (results) | $1.39 |
| May 7, 2025 | 8-K Item 2.02 (results) | $1.31 |
| Feb 26, 2025 | 8-K Item 2.02 (results) | $1.61 |
| Jan 13, 2025 | 8-K Item 2.02 (results) | $2.98 |
| Nov 7, 2024 | 8-K Item 2.02 (results) | $4.29 |
| Aug 8, 2024 | 8-K Item 2.02 (results) | — |
| May 2, 2024 | 8-K Item 2.02 (results) | — |
| Feb 28, 2024 | 8-K Item 2.02 (results) | — |
| Jan 8, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)AbbVie (ABBV)Merck (MRK)Abbott Laboratories (ABT)Vertex Pharmaceuticals Inc / Ma (VRTX)Pfizer (PFE)Bristol Myers Squibb (BMY)Astrazeneca (AZN)Regeneron Pharmaceuticals (REGN)
Popular today
Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)
More on GERN
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.